Physician profile
Bimaljit K Mann
NPI 1912378217
$1,637.06
in general payments reported to CMS, 2019-2025
16 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $309 · 2023: $409 · 2024: $491 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $490.00 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $217.91 | 2023 | |
| Alk-Abello, INC | $149.76 | 2024 | Odactra, Grastek |
| Bayer Healthcare Pharmaceuticals INC. | $135.60 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $110.65 | 2022 | |
| Boston Scientific Corporation | $84.08 | 2022 | |
| Pfizer INC. | $73.40 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $66.95 | 2023-2024 | Pifeltro, Delstrigo, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $63.26 | 2022-2024 | Spravato |
| Glaxosmithkline, LLC. | $54.66 | 2022-2024 | Trelegy Ellipta, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $42.51 | 2022-2025 | Breztri |
| Novo Nordisk INC | $42.08 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $35.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.81 | 2023 | Jardiance |
| Hologic Sales and Service, LLC | $20.12 | 2025 | Aptima |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.37 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimaljit Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.